INR 281.45
(1.81%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|---|
Operating Cash Flow | 213.7 Million | -52.8 Million | 11.9 Million | 259 Million | 72.6 Million | -30.25 Million |
Net Income | 185.6 Million | 134.4 Million | 186.5 Million | 106.5 Million | 106.5 Million | 209.52 Million |
Depreciation & Amortization | 9.7 Million | 11.4 Million | 8.7 Million | 12.9 Million | 9.9 Million | 3.85 Million |
Deferred income taxes | - | - | - | -51.4 Million | -60.3 Million | -7.8 Million |
Stock-based compensation | - | 2.7 Million | 15.3 Million | 36.9 Million | 38.3 Million | 7.8 Million |
Change in working capital | 63.8 Million | -147.3 Million | -148.2 Million | 176 Million | -16.5 Million | -217.96 Million |
Other non-cash items | -53.3 Million | -54 Million | -50.4 Million | -21.9 Million | -5.3 Million | -25.67 Million |
Investing Cash Flow | -262.6 Million | 34.5 Million | -476.3 Million | -125.6 Million | -25.5 Million | -23.24 Million |
Investments in PPE | -1.9 Million | -3.5 Million | -19.1 Million | -8.5 Million | -33.2 Million | -20.8 Million |
Acquisitions | - | 800 Thousand | - | 1.8 Million | 4.4 Million | 6.28 Million |
Investment purchases | -391.3 Million | -87.4 Million | -493.9 Million | -1.12 Billion | -4.3 Million | -151.65 Million |
Sales/Maturities of investments | 5.6 Million | 77.6 Million | 2.5 Million | 984.6 Million | -4.4 Million | 145.25 Million |
Other Investing Activities | -178.3 Million | 47 Million | 34.2 Million | 23 Million | 12 Million | -2.31 Million |
Financing Cash Flow | 38.1 Million | -60.4 Million | 337.3 Million | -2.3 Million | -35.6 Million | 43.34 Million |
Debt repayment | -200 Thousand | -50.2 Million | -47.1 Million | -1.2 Million | -33.5 Million | -41.7 Million |
Dividends payments | -16.2 Million | -71.7 Million | -119.3 Million | - | - | - |
Common Stock Repurchased | - | - | -47.1 Million | - | - | - |
Common Stock Issuance | 54.5 Million | 69.8 Million | 414 Million | - | - | 86.42 Million |
Other Financing Activities | 54.3 Million | -8.3 Million | 136.8 Million | -1.1 Million | -2.1 Million | -1.38 Million |
Accounts receivables | 27.1 Million | -124.6 Million | 1.6 Million | 18.2 Million | 189.7 Million | -207.2 Million |
Accounts payables | 200 Thousand | -1 Million | -20.9 Million | 500 Thousand | 20.2 Million | 900 Thousand |
Inventory | - | - | 100 Thousand | -145.3 Million | -109.3 Million | -55.46 Million |
Other working capital | 36.5 Million | -21.7 Million | -129 Million | 302.6 Million | -117.1 Million | 43.8 Million |
Cash at beginning of period | 19.4 Million | 98.1 Million | 230.6 Million | 99 Million | 8.7 Million | 53.57 Million |
Cash at end of period | 388.2 Million | 19.4 Million | 103.5 Million | 230.1 Million | 20.1 Million | 43.42 Million |
Capital Expenditure | -1.9 Million | -3.5 Million | -19.1 Million | -8.5 Million | -33.2 Million | -20.8 Million |
Effect of forex changes on cash | - | - | - | - | -100 Thousand | 1000.00 |
Net cash flow / Change in cash | 368.8 Million | -78.7 Million | -127.1 Million | 131.1 Million | 11.4 Million | -10.15 Million |
Free Cash Flow | 211.8 Million | -56.3 Million | -7.2 Million | 250.5 Million | 39.4 Million | -51.06 Million |
Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 121 Million | 185.6 Million | 16.5 Million | 79.3 Million | 39.5 Million | 50.3 Million |
Depreciation & Amortization | - | 9.7 Million | - | 2.4 Million | 2.6 Million | 2.2 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | - | 63.8 Million | - | - | - | - |
Other non-cash items | -121 Million | -53.3 Million | -16.5 Million | -79.3 Million | -39.5 Million | -50.3 Million |
Investing Cash Flow | - | -262.6 Million | - | - | - | - |
Investments in PPE | - | -1.9 Million | - | - | - | - |
Acquisitions | - | - | - | - | - | - |
Investment purchases | - | -391.3 Million | - | - | - | - |
Sales/Maturities of investments | - | 5.6 Million | - | - | - | - |
Other Investing Activities | - | -178.3 Million | - | - | - | - |
Financing Cash Flow | - | 38.1 Million | - | - | - | - |
Debt repayment | - | -200 Thousand | - | - | - | - |
Dividends payments | - | -16.2 Million | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | 54.5 Million | - | - | - | - |
Other Financing Activities | - | 54.3 Million | - | - | - | - |
Accounts receivables | - | 27.1 Million | - | - | - | - |
Accounts payables | - | 200 Thousand | - | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | - | 36.5 Million | - | - | - | - |
Cash at beginning of period | - | 19.4 Million | - | 53.5 Million | 48.3 Million | 19.4 Million |
Cash at end of period | - | 388.2 Million | - | 58.3 Million | 53.5 Million | 23.8 Million |
Capital Expenditure | - | -1.9 Million | - | - | - | - |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | - | 368.8 Million | - | 4.8 Million | 5.2 Million | 4.4 Million |
Free Cash Flow | - | 211.8 Million | - | 4.8 Million | 5.2 Million | 4.4 Million |
AUROPHARMA
3075
9385
VEOEY
JASH
4320